Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

Taiji Goto, Akiko Shiina, Toshiharu Yoshino, Kiyoshi Mizukami, Kazuki Hirahara, Osamu Suzuki, Yoshitaka Sogawa, Tomoko Takahashi, Tsuyoshi Mikkaichi, Naoki Nakao, Mizuki Takahashi, Masashi Hasegawa, Shigeki Sasaki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, ip). Furthermore, based on the X-ray crystallography of 10f bound to the human PDE4B catalytic domain, we designed 7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-one derivative 39 which has a fused bicyclic lactam scaffold. Compound 39 exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) production in mouse splenocytes (IC 50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).

Original languageEnglish
Pages (from-to)7025-7037
Number of pages13
JournalBioorganic and Medicinal Chemistry
Volume21
Issue number22
DOIs
Publication statusPublished - Nov 15 2013

Fingerprint

Phosphodiesterase 4 Inhibitors
Lipopolysaccharides
Derivatives
Inhibitory Concentration 50
Lactams
Lung
X ray crystallography
X Ray Crystallography
Carboxylic Acids
Scaffolds
Catalytic Domain
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. / Goto, Taiji; Shiina, Akiko; Yoshino, Toshiharu; Mizukami, Kiyoshi; Hirahara, Kazuki; Suzuki, Osamu; Sogawa, Yoshitaka; Takahashi, Tomoko; Mikkaichi, Tsuyoshi; Nakao, Naoki; Takahashi, Mizuki; Hasegawa, Masashi; Sasaki, Shigeki.

In: Bioorganic and Medicinal Chemistry, Vol. 21, No. 22, 15.11.2013, p. 7025-7037.

Research output: Contribution to journalArticle

Goto, T, Shiina, A, Yoshino, T, Mizukami, K, Hirahara, K, Suzuki, O, Sogawa, Y, Takahashi, T, Mikkaichi, T, Nakao, N, Takahashi, M, Hasegawa, M & Sasaki, S 2013, 'Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors', Bioorganic and Medicinal Chemistry, vol. 21, no. 22, pp. 7025-7037. https://doi.org/10.1016/j.bmc.2013.09.013
Goto, Taiji ; Shiina, Akiko ; Yoshino, Toshiharu ; Mizukami, Kiyoshi ; Hirahara, Kazuki ; Suzuki, Osamu ; Sogawa, Yoshitaka ; Takahashi, Tomoko ; Mikkaichi, Tsuyoshi ; Nakao, Naoki ; Takahashi, Mizuki ; Hasegawa, Masashi ; Sasaki, Shigeki. / Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. In: Bioorganic and Medicinal Chemistry. 2013 ; Vol. 21, No. 22. pp. 7025-7037.
@article{4718dacf9c1844a89186b9b61a144dc4,
title = "Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors",
abstract = "5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, ip). Furthermore, based on the X-ray crystallography of 10f bound to the human PDE4B catalytic domain, we designed 7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-one derivative 39 which has a fused bicyclic lactam scaffold. Compound 39 exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) production in mouse splenocytes (IC 50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41{\%} inhibition at a dose of 1.0 mg/kg, i.t.).",
author = "Taiji Goto and Akiko Shiina and Toshiharu Yoshino and Kiyoshi Mizukami and Kazuki Hirahara and Osamu Suzuki and Yoshitaka Sogawa and Tomoko Takahashi and Tsuyoshi Mikkaichi and Naoki Nakao and Mizuki Takahashi and Masashi Hasegawa and Shigeki Sasaki",
year = "2013",
month = "11",
day = "15",
doi = "10.1016/j.bmc.2013.09.013",
language = "English",
volume = "21",
pages = "7025--7037",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "22",

}

TY - JOUR

T1 - Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

AU - Goto, Taiji

AU - Shiina, Akiko

AU - Yoshino, Toshiharu

AU - Mizukami, Kiyoshi

AU - Hirahara, Kazuki

AU - Suzuki, Osamu

AU - Sogawa, Yoshitaka

AU - Takahashi, Tomoko

AU - Mikkaichi, Tsuyoshi

AU - Nakao, Naoki

AU - Takahashi, Mizuki

AU - Hasegawa, Masashi

AU - Sasaki, Shigeki

PY - 2013/11/15

Y1 - 2013/11/15

N2 - 5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, ip). Furthermore, based on the X-ray crystallography of 10f bound to the human PDE4B catalytic domain, we designed 7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-one derivative 39 which has a fused bicyclic lactam scaffold. Compound 39 exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) production in mouse splenocytes (IC 50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).

AB - 5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, ip). Furthermore, based on the X-ray crystallography of 10f bound to the human PDE4B catalytic domain, we designed 7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-one derivative 39 which has a fused bicyclic lactam scaffold. Compound 39 exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) production in mouse splenocytes (IC 50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).

UR - http://www.scopus.com/inward/record.url?scp=84885847217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885847217&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2013.09.013

DO - 10.1016/j.bmc.2013.09.013

M3 - Article

C2 - 24094436

AN - SCOPUS:84885847217

VL - 21

SP - 7025

EP - 7037

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 22

ER -